Aspergillus infections after lung transplantation

Infectious Diseases in Clinical Practice

Volumn 14, Issue 5, 2006, Pages 283-288

  Day, Larry J ^a   Chenoweth, Carol E ^b,c   Hyde, Kristi Vander ^c   Lynch, Joseph P ^d   Iannettoni, Mark ^e   Clark, Nina M ^f  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UCLA MEDICAL CENTER   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AZATHIOPRINE; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFUROXIME; CORTICOSTEROID; CYCLOSPORIN A; ITRACONAZOLE; METHYLPREDNISOLONE; PREDNISONE; VANCOMYCIN;

ADULT; ARTICLE; ASPERGILLUS; CONTROLLED STUDY; DEMOGRAPHY; ENVIRONMENTAL EXPOSURE; FEMALE; FUNGAL COLONIZATION; GENERAL ASPECTS OF DISEASE; GRAFT RECIPIENT; HUMAN; INFECTION RISK; LUNG ASPERGILLOSIS; LUNG TRANSPLANTATION; MALE; MEDICAL RECORD; MYCOSIS; POSTOPERATIVE CARE; RISK FACTOR; TRACHEOBRONCHITIS;

EID: 33748806816     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000230548.96251.70     Document Type: Article

References (38)

1. Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transpl Infect Dis. 2001;3(3):128-137.
2. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32(3):358-366.
3. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore). 1999;78(2):123-138.
4. Panackal AA, Dahlman A, Keil KT, et al. Outbreak of invasive aspergillosis among renal transplant recipients. Transplantation. 2003;75(7):1050-1053.
5. Lai KK. A cluster of invasive aspergillosis in a bone marrow transplant unit related to construction and the utility of air sampling. Am J Infect Control. 2001;29(5):333-337.
6. Oren I, Haddad N, Finkelstein R, et al. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol. 2001;66(4):257-262.
7. Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis. 2002;4(4):195-200.
8. Arcasoy SM, Kotloff RM. Lung transplantation. N Engl J Med. 1999;340(14):1081-1091.
9. Nathan SD, Shorr AF, Schmidt ME, et al. Aspergillus and endobronchial abnormalities in lung transplant recipients. Chest. 2000;118(2):403-407.
10. Nunley DR, Gal AA, Vega JD, et al. Saprophytic fungal infections and complications involving the bronchial anastomosis following human lung transplantation. Chest. 2002;122(4):1185-1191.
11. Mehrad B, Paciocco G, Martinez FJ, et al. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest. 2001;119(1):169-175.
12. Egan JJ, Yonan N, Carroll KB, et al. Allergic bronchopulmonary aspergillosis in lung allograft recipients. Eur Respir J. 1996;9(1):169-171.
13. Cattelan AM, Loy M, Tognon S, et al. An unusual presentation of invasive aspergillosis after lung transplantation. Transpl Int. 2000;13(3):183-186.
14. Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis. 2001;33(11):1824-1833.
15. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med. 1996;100(2):171-178.
16. Cahill BC, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest. 1997;112(5):1160-1164.
17. Kanj SS, Tapson V, Davis RD, et al. Infections in patients with cystic fibrosis following lung transplantation. Chest. 1997;112(4):924-930.
18. Helmi M, Love RB, Welter D, et al. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest. 2003;123(3):800-808.
19. Nunley DR, Ohori P, Grgurich WF, et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest. 1998;114(5):1321-1329.
20. Westney GE, Kesten S, De Hoyos A, et al. Aspergillus infection in single and double lung transplant recipients. Transplantation. 1996;61(6):915-919.
21. Husni RN, Gordon SM, Longworth DL, et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis. 1998;26(3):753-755.
22. Gordon SM, Avery RK. Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies. Transpl Infect Dis. 2001;3(3):161-167.
23. Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant. 2003;17(2):77-88.
24. Cadillo-Chavez R, de Echegaray S, Santiago-Delpin EA, et al. Assessing the risk of infection and rejection in Hispanic renal transplant recipients by means of an adenosine triphosphate release assay. Transplant Proc. 2006;38(3):918-920.
25. Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis. 2000;31(2):545-553.
26. Hamacher J, Spiliopoulos A, Kurt AM, et al. Pre-emptive therapy with azoles in lung transplant patients. Geneva Lung Transplantation Group. Eur Respir J. 1999;13(1):180-186.
27. Patterson TF, Peters J, Levine SM, et al. Systemic availability of itraconazole in lung transplantation. Antimicrob Agents Chemother. 1996;40(9):2217-2220.
28. Fungal infections. Am J Transplant. 2004;4(suppl 10):110-134.
29. Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol. 1997;52(3):235-237.
30. Glasmacher A, Hahn C, Molitor E, et al. Itraconazole through concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses. 1999;42(11-12):591-600.
31. Mattner F, Weissbrodt H, Strueber M. Two case reports: fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient. Scand J Infect Dis. 2004;36(4):312-314.
32. Reichenspurner H, Gamberg P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc. 1997;29(1-2):627-628.
33. Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant. 2001;20(12):1274-1281.
34. Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation. 2001;72(3):545-548.
35. Drew RH, Dodds Ashley E, Benjamin DK Jr, et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation. 2004;77(2):232-237.
36. Patterson JE, Peters J, Calhoon JH, et al. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients. Transpl Infect Dis. 2000;2(1):22-28.
37. Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood. 2003;101(7):2542-2546.
38. Warris A, Gaustad P, Meis JF, et al. Recovery of filamentous fungi from water in a paediatric bone marrow transplantation unit. J Hosp Infect. 2001;47(2):143-148.